Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
2.

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.

Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK.

Mol Cancer Ther. 2015 Dec;14(12):2677-86. doi: 10.1158/1535-7163.MCT-14-0630. Epub 2015 Oct 29.

3.

Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.

Hainsworth JD, Thompson DS, Bismayer JA, Gian VG, Merritt WM, Whorf RC, Finney LH, Dudley BS.

Cancer Med. 2015 May;4(5):673-81. doi: 10.1002/cam4.376. Epub 2014 Dec 31.

4.

A novel platform for detection of CK+ and CK- CTCs.

Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AK.

Cancer Discov. 2011 Dec;1(7):580-6. doi: 10.1158/2159-8290.CD-11-0215. Epub 2011 Nov 3.

5.

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.

Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Dec 15;10(12):1306-14. Epub 2010 Dec 15.

6.

Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.

Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK.

Mol Cancer Ther. 2010 Aug;9(8):2377-88. doi: 10.1158/1535-7163.MCT-10-0200. Epub 2010 Aug 3.

7.

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.

Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK.

J Clin Invest. 2010 May;120(5):1515-23. doi: 10.1172/JCI40802. Epub 2010 Apr 12.

8.

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK.

Mol Cancer Ther. 2010 Apr;9(4):985-95. doi: 10.1158/1535-7163.MCT-09-0967. Epub 2010 Apr 6.

9.

The dicey role of Dicer: implications for RNAi therapy.

Merritt WM, Bar-Eli M, Sood AK.

Cancer Res. 2010 Apr 1;70(7):2571-4. doi: 10.1158/0008-5472.CAN-09-2536. Epub 2010 Feb 23. Review.

10.

Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.

Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK.

Cancer Biol Ther. 2009 Dec;8(23):2263-72. Epub 2009 Dec 19.

11.

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.

Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK.

Cancer Biol Ther. 2009 Aug;8(16):1596-603. Epub 2009 Aug 13.

12.

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.

Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK.

Cancer. 2009 Jun 15;115(12):2684-92. doi: 10.1002/cncr.24335.

13.

Dicer, Drosha, and outcomes in patients with ovarian cancer.

Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK.

N Engl J Med. 2008 Dec 18;359(25):2641-50. doi: 10.1056/NEJMoa0803785. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.

14.

Functional significance of VEGFR-2 on ovarian cancer cells.

Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK.

Int J Cancer. 2009 Mar 1;124(5):1045-53. doi: 10.1002/ijc.24028.

15.

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.

Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK.

Neoplasia. 2008 Nov;10(11):1259-67.

16.

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK.

Clin Cancer Res. 2008 Sep 1;14(17):5437-46. doi: 10.1158/1078-0432.CCR-07-4922.

17.

Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.

Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK.

Cancer Res. 2008 Jul 15;68(14):5849-58. doi: 10.1158/0008-5472.CAN-07-6130.

18.

HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.

Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK.

Clin Cancer Res. 2008 Jun 1;14(11):3372-9. doi: 10.1158/1078-0432.CCR-07-4433.

19.

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.

Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK.

Am J Obstet Gynecol. 2008 Apr;198(4):477.e1-9; discussion 477.e9-10. doi: 10.1016/j.ajog.2007.12.028. Erratum in: Am J Obstet Gynecol. 2018 Sep;219(3):302.

20.

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.

Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK.

J Natl Cancer Inst. 2008 Mar 5;100(5):359-72. doi: 10.1093/jnci/djn024. Epub 2008 Feb 26.

21.

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.

Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN Jr, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK.

Clin Cancer Res. 2007 Dec 15;13(24):7487-95.

22.

Markers of angiogenesis in ovarian cancer.

Merritt WM, Sood AK.

Dis Markers. 2007;23(5-6):419-31. Review.

23.

Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.

Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK.

Cancer Res. 2007 Nov 15;67(22):10976-83. Erratum in: Cancer Res. 2018 Jul 15;78(14):4100.

24.

Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.

Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK.

Cancer Res. 2007 Oct 1;67(19):9337-45.

25.

Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.

Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK.

Clin Cancer Res. 2007 Jul 15;13(14):4209-17.

26.

Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.

Landen CN Jr, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson DM, Brinkley WR, Sood AK.

Clin Cancer Res. 2007 Jul 15;13(14):4098-104.

27.

Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.

Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK.

Clin Cancer Res. 2007 Jun 1;13(11):3423-30.

28.

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.

Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK.

Cancer Res. 2007 Jan 1;67(1):281-8. Erratum in: Cancer Res. 2018 Jul 15;78(14):4099.

29.

EphA2 overexpression is associated with angiogenesis in ovarian cancer.

Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK.

Cancer. 2007 Jan 15;109(2):332-40.

30.

Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.

Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK.

Cancer Biol Ther. 2006 Dec;5(12):1708-13. Epub 2006 Dec 30.

PMID:
17106249
31.

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.

Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.

J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70.

PMID:
17077358
32.

Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.

Merritt WM, Thaker PH, Landen CN Jr, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK.

Cancer Biol Ther. 2006 Oct;5(10):1357-60. Epub 2006 Oct 31.

PMID:
16969087
33.

Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma.

Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN Jr, Lu C, Gershenson DM, Simpson JL, Sood AK.

Cancer Biol Ther. 2006 Oct;5(10):1369-74. Epub 2006 Oct 26.

PMID:
16969071
34.

Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.

Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA 3rd, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK.

Cancer Res. 2006 Sep 1;66(17):8633-9.

35.

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2006 Aug 15;12(16):4916-24. Erratum in: Clin Cancer Res. 2019 May 15;25(10):3194.

36.

Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.

Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK.

Nat Med. 2006 Aug;12(8):939-44. Epub 2006 Jul 23.

PMID:
16862152
37.

Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure.

Houck WV, Pan LC, Kribbs SB, Clair MJ, McDaniel GM, Krombach RS, Merritt WM, Pirie C, Iannini JP, Mukherjee R, Spinale FG.

Circulation. 1999 Nov 9;100(19):2003-9.

PMID:
10556227
38.

Amlodipine monotherapy, angiotensin-converting enzyme inhibition, and combination therapy with pacing-induced heart failure.

Kribbs SB, Merritt WM, Clair MJ, Krombach RS, Houck WV, Dodd MG, Mukherjee R, Spinale FG.

Hypertension. 1998 Mar;31(3):755-65.

PMID:
9495258
39.

Chondroblastoma of the pelvis suggestive of malignancy.

McLaughlin RE, Sweet DE, Webster T, Merritt WM.

J Bone Joint Surg Am. 1975 Jun;57(4):549-51. No abstract available.

PMID:
1141269

Supplemental Content

Loading ...
Support Center